WCN26-8280 IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MINIMAL CHANGE DISEASE - A CASE OF SUCCESSFUL RECHALLENGE

Read full text Summarise with VIRAT
Authors: Hariharan Seshadri, Evelyn Acosta, Amanda S. Tchakarov, Larissa Alejandra Meyer, Jamie S. Lin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Immune checkpoint inhibitors (ICI) are a broad class of immunotherapy drugs used across a wide range of malignancies, but these treatments can also cause autoimmune complications. Minimal change disease (MCD) is rare side effect of ICI therapy and re-challenge of ICI therapy after treatment of MCD has been infrequently reported. We present the first case of successful ICI-rechallenge using low-dose steroid bridging resulting in sustained remission of proteinuria and continued oncologic response.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104174–104174
Publication date
25 March 2026
Language
EN